AbstractThe elicitation of broadly neutralizing antibodies directed against the human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins, gp120 and gp41, remains a major challenge. Attempts to utilize monomeric gp120 as an immunogen to elicit high titers of neutralizing antibodies have been disappointing. Envelope glycoprotein constructs that better reflect the trimeric structure of the functional envelope spike have exhibited improved immunogenicity compared with monomeric gp120. We have described soluble gp140 ectodomain constructs with a heterologous trimerization motif; these have previously been shown to elicit antibodies in mice that were able to neutralize a number of HIV-1 isolates, among them primary isolate viruses. Rece...
Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) during chronic...
The HIV-1 envelope glycoproteins gp120 and gp41 mediate binding and fusion of the virus to target ce...
Development of new immunogens eliciting broadly neutralizing antibodies (bNAbs) is a main priority f...
AbstractThe human immunodeficiency virus type 1 (HIV-1) surface envelope glycoprotein (Env) complex,...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
AbstractEfficient immune responses to HIV-1 gene products are essential elements to the development ...
The high HIV-1 viral diversity is a formidable hurdle for the development of an HIV-1 vaccine. Elici...
AbstractA critical component of an effective HIV vaccine will be the induction of broadly neutralizi...
AbstractThe external domains of the HIV-1 envelope glycoprotein (gp120 and the gp41 ectodomain, coll...
Abstract An effective human immunodeficiency virus type I (HIV-1) vaccine that robustly elicits broa...
Background: Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) du...
BACKGROUND: Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) du...
<div><p>Background</p><p>Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodi...
Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) during chronic...
Recombinant soluble HIV-1 envelope glycoprotein (Env) SOSIP trimers are a design platform for induci...
Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) during chronic...
The HIV-1 envelope glycoproteins gp120 and gp41 mediate binding and fusion of the virus to target ce...
Development of new immunogens eliciting broadly neutralizing antibodies (bNAbs) is a main priority f...
AbstractThe human immunodeficiency virus type 1 (HIV-1) surface envelope glycoprotein (Env) complex,...
The high viral diversity of HIV-1 is a formidable hurdle for the development of an HIV-1 vaccine. El...
AbstractEfficient immune responses to HIV-1 gene products are essential elements to the development ...
The high HIV-1 viral diversity is a formidable hurdle for the development of an HIV-1 vaccine. Elici...
AbstractA critical component of an effective HIV vaccine will be the induction of broadly neutralizi...
AbstractThe external domains of the HIV-1 envelope glycoprotein (gp120 and the gp41 ectodomain, coll...
Abstract An effective human immunodeficiency virus type I (HIV-1) vaccine that robustly elicits broa...
Background: Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) du...
BACKGROUND: Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) du...
<div><p>Background</p><p>Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodi...
Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) during chronic...
Recombinant soluble HIV-1 envelope glycoprotein (Env) SOSIP trimers are a design platform for induci...
Ten to 30% of HIV-1 infected subjects develop broadly neutralizing antibodies (bNAbs) during chronic...
The HIV-1 envelope glycoproteins gp120 and gp41 mediate binding and fusion of the virus to target ce...
Development of new immunogens eliciting broadly neutralizing antibodies (bNAbs) is a main priority f...